Bispecific Antibodies Linked to Serious Infections
A four-center international cohort of 285 lymphoma patients finds infection risk is highest in the early months of treatment.
Updated on Nov. 22, 2026 in Cancer

A retrospective cohort study of 285 patients treated with CD3xCD20 bispecific antibodies for B-cell non-Hodgkin lymphoma found 42% experienced at least one infection. Authors recommend heightened infection surveillance during the first 90 days of treatment.
Why it matters
The findings suggest that patients receiving these therapies may need closer monitoring for infection, particularly those with low antibody levels. The study points to a modifiable risk factor that clinicians may be able to address proactively.
The cohort reported a one-year cumulative incidence of any infection of 36% and grade 3 or higher infection of 19%, with 61% of infections in the respiratory tract. Because the design is retrospective across 285 patients, the results do not yet show whether preventive interventions change these rates.
The players
Peter Mac
Peter MacCallum Cancer Centre is a major Australian cancer research and treatment institution and one of the four participating study centers.
The details
The study followed patients treated with epcoritamab, glofitamab or mosunetuzumab, drugs that bind both T cells and CD20 on B cells. CD20 is also found on normal B cells, so treatment depletes healthy B cells, impairing antibody production. Antimicrobial prophylaxis against HSV/VZV was used in 96% of patients and against PJP in 86%.
Timeline
The recommended period for heightened infection surveillance is the first 90 days of treatment.
The cohort's median follow-up was 21 months.
Cumulative infection incidence was measured at one year.
Health Landscape
As bispecific antibodies become standard options for relapsed B-cell lymphoma, their infection profile is emerging as a central safety consideration. The study adds real-world data on how B-cell depletion translates into prolonged immunodeficiency across several drugs in the class.
Patients receiving these treatments may benefit from asking their care team about infection monitoring, antimicrobial prophylaxis, and whether their antibody levels should be checked during therapy. Discussing immunoglobulin replacement with a clinician is a reasonable step for those at higher risk.
The takeaway
Monitoring antibody levels and watching closely for infection in the first three months of treatment may help identify patients who need extra protection. Clinicians and patients should discuss these steps before starting therapy.
Further reading
For related coverage, see our Cancer section.
Source note: This article includes information reported by Oncodaily - Oncology News, Insights, Stories.



